Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Endocrine therapy

Acknowledgements

Membership of NBOCC* endocrine therapy subgroup

This guideline was developed by a multidisciplinary working group convened by NBOCC*:

Dr Catherine Shannon Medical Oncologist (Chair)
Ms Denice Bassanelli Consumer Representative
Dr Richard De Boer Medical Oncologist
Dr Nicole McCarthy Medical Oncologist
Ms Janet Rice Nurse
Professor Patsy Yates Nurse

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Membership of NBOCC* advanced breast cancer guidelines working group

The development of this guideline was overseen by a multidisciplinary working group convened by NBOCC*: Dr Karen Luxford (Facilitator), Dr David Blakey, Professor Phyllis Butow, Ms Helen Collyner, Ms Sally Crossing, Associate Professor Jane Dahlstrom, Dr Craig Murphy, Ms Janet Rice, Dr Catherine Shannon, Ms Ann Town, Professor Patsy Yates

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

NBOCC* staff

Ms Ornella Care Senior Project Officer (Project lead)
Dr Karen Luxford General Manager
Ms Alison Pearce Program Manager

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Systematic review

NBOCC* gratefully acknowledges the work of Dr Suzanne Campbell at Health Technology Analyst Pty Ltd in developing the systematic review Evidence on the use of endocrine therapy for post-menopausal women with metastatic breast cancer (2008), which informed the development of this guideline

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

External review

NBOCC* acknowledges those who gave their time to provide comment on the draft guideline recommendations as part of the external review process.

Full details of trial results are provided in the document Evidence on the use of endocrine therapy for post-menopausal women with metastatic breast cancer (2008), which can be accessed via the NBOCC* website at www.nbocc.org.au

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Acknowledgement

The National Breast Cancer Foundation provided funding for the development and production of this guideline

Pharmaceutical benefits scheme

Pharmaceutical Benefits Scheme indications for drugs mentioned in this guideline (as of 1 march 2008). For updates after this date go to http://www.pbs.gov.au

Anastrozole Treatment of hormone-dependent breast cancer in post-menopausal women
Exemestane Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate
Letrozole Treatment of hormone-dependent advanced breast cancer in post-menopausal women
Goserelin Hormone-dependent locally advanced (equivalent to stage III) or metastatic (equivalent to stage IV)breast cancer in pre-menopausal women
Megestrol acetate Treatment of hormone-dependent advanced breast cancer
Tamoxifen Treatment of hormone-dependent breast cancer. This drug is not subsided for the primary prevention of breast cancer

Development process

Priority topic areas for NBOCC* guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded. The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Recommendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer was prepared and produced by:

National Breast and Ovarian Cancer Centre*
Level 1, Suite 103, 355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Frecall 1800 624 973
Website: www.nbocc.org.au

Cancer Australia 2011
ISBN Print: 978-1-74127-089-1 Online: 978-1-74127-094-5 CIP : 11545

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from National Breast and Ovarian Cancer
Centre*. Requests and enquiries concerning reproduction and rights should be addressed to Corporate Communications Manager, National Breast and Ovarian Cancer Centre*.

Recommended citation
National Breast and Ovarian Cancer Centre*. Recommendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer. National Breast and Ovarian Cancer Centre*, Surry Hills, NSW, 2010.

Disclaimer
National Breast and Ovarian Cancer Centre* does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre* develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.

National Breast and Ovarian Cancer Centre* is funded by the Australian Government Department of Health and Ageing.

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Published using CeCC Docbook Manager